Boehringer Ingelheim reported Phase 3 success for its dual-acting obesity therapy survodutide, announcing significantly greater weight loss versus placebo in a trial of 725 participants. In results covering up to 76 weeks, patients receiving survodutide lost substantially more weight, with analyses focusing on those who stayed on treatment through evaluation. The program also met a co-primary responder goal, with a larger share of survodutide-treated participants achieving at least 5% weight loss compared with placebo. Investigators additionally assessed body composition measures including waist circumference, and company notes indicated potential preservation of muscle mass. Analysts will likely press for further details on adverse events, durability of effects, and comparative performance versus other GLP-1 and dual-incretin competitors. The muscle-preservation angle is a key commercial and clinical differentiator because weight-loss therapies can reduce lean body mass. For the obesity market, another late-stage win tightens competition and accelerates follow-on evidence generation, including in liver disease populations.